Literature DB >> 279010

Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes.

D E Chenoweth, T E Hugli.   

Abstract

Human C5a, a complement-derived anaphylatoxin, is a potent mediator of human leukocyte chemotaxis. Using a homogeneous preparation of C5a that was 125I-labeled, we have demonstrated the presence of a specific cellular receptor for this glycoprotein on intact human polymorphonuclear leukocytes. Cellular uptake of the radiolabeled ligand occurred rapidly and the rate of dissociation was extremely slow. Cellular binding was saturable with respect to 125I-labeled C5a, and half-saturation occurred at a concentration of 3-7 X 10(-9) M. The number of C5a binding sites per cell was estimated as 1-3 X 10(5). The ligand (C5a) displays specific structural features that are required for binding because analogs of C5a such as C5ades Arg or a yeast carboxypeptidase-digested C5a derivative C5a-(I-69) inhibited the binding but C3a anaphylatoxin, which resembles C5a chemically, did not. Both C5a-mediated leukocyte chemotaxis and C5a-induced lysosomal enzyme release from cytochalasin B-treated cells closely paralleled uptake of the ligand, clearly indicating that it is a receptor-C5a interaction that leads to stimulation of these cellular responses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 279010      PMCID: PMC392905          DOI: 10.1073/pnas.75.8.3943

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  A simple in vitro method for studies on chemotaxis.

Authors:  J E Cutler; J J Munoz
Journal:  Proc Soc Exp Biol Med       Date:  1974-11

Review 4.  Membrane receptors.

Authors:  P Cuatrecasas
Journal:  Annu Rev Biochem       Date:  1974       Impact factor: 23.643

5.  Mechanisms of lysosomal enzyme release from human leukocytes: microtubule assembly and membrane fusion induced by a component of complement.

Authors:  I Goldstein; S Hoffstein; J Gallin; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

6.  Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation.

Authors:  I M Goldstein; M Brai; A G Osler; G Weissmann
Journal:  J Immunol       Date:  1973-07       Impact factor: 5.422

7.  The binding of labelled tetrodotoxin to non-myelinated nerve fibres.

Authors:  D Colquhoun; R Henderson; J M Ritchie
Journal:  J Physiol       Date:  1972-12       Impact factor: 5.182

8.  Demonstration of a receptor on rabbit neutrophils for chemotactic peptides.

Authors:  S Aswanikumar; B Corcoran; E Schiffmann; A R Day; R J Freer; H J Showell; E L Becker
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

9.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

10.  Purification and partial characterization of human and porcine C3a anaphylatoxin.

Authors:  T E Hugli; E H Vallota; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1975-02-25       Impact factor: 5.157

View more
  115 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  15-hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits the LTB4-induced skin response.

Authors:  T Ternowitz; P H Andersen; P Bjerring; K Fogh; J M Schröder; K Kragballe
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

3.  The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.

Authors:  A Fayyazi; O Scheel; T Werfel; S Schweyer; M Oppermann; O Götze; H J Radzun; J Zwirner
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

4.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

Review 5.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

6.  Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.

Authors:  Mads Lausen; Mathilde Selmar Pedersen; Nareen Sherzad Kader Rahman; Liv Therese Holm-Nielsen; Faduma Yahya Mohamed Farah; Gunna Christiansen; Svend Birkelund
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

7.  Receptor-mediated activation of a phospholipase A2 in rabbit neutrophil plasma membrane.

Authors:  B J Bormann; C K Huang; W M Mackin; E L Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

Review 8.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

9.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

10.  NPC 15669-modulated human polymorphonuclear neutrophil functional responsiveness: effects on receptor-coupled signal transduction.

Authors:  R J Smith; J M Justen; J E Bleasdale; L M Sly
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.